Hi Visitor,

Nerve Access, Inc.

Nerve Access, Inc. is a biotechnology company that was founded to conduct quality research and manufacturing of pharmaceuticals and other medical products, with a special focus on therapeutics that can enhance regeneration and functional recovery of the Central Nervous System (CNS) after neurological disorders such as Alzheimer's, stroke, Parkinson's, spinal cord ...

Read more ...

Prev Next

Location

 

Mailing List Subscription

1 1 1 1 1 1 1 1 1 1

Alzheimer's disease (AD) was first described by a German psychiatrist Alois Alzheimer in 1906 and was named after him.  Generally, Alzheimer's disease is diagnosed in people over 65 years of age. An estimated 26.6 million people worldwide had Alzheimer's in 2006.  About 35 million patients with some degree of the disease was reported in 2009; 5.3 million of these patients are in the USA .  These numbers are expected to quadruple by 2050.

Alzheimer's disease is characterized by cognitive decline with the most commonly recognized symptom is memory loss, such as difficulty in remembering recently learned facts. As the disease progresses, the patient suffers mood swings, language breakdown, confusion, irritability and aggression, and long-term memory loss.

To Learn about Alzheimer's disease, download this PDF file.  More info is also available at www.neuralrepairinstitute.org.

Business Information

The Opportunity:

It is estimated that approximately 5.4 million patients in the USA suffer from Alzheimer’s disease (AD), and that an additional million baby boomers will develop AD during their lifetime.  On a worldwide basis there are approximately 35.5 million AD patients.  While a great deal of time and attention has been paid to the treatment of AD, as reflected by the approximately $7 billion annually spent worldwide on AD drugs worldwide (with that amount projected to grow to up to $20 billion annually), the existing AD treatments produce only mild improvements, and are efficacious for a very limited period (18 to 24 months).   Based on these market dynamics, a highly efficacious long-term treatment for AD would have tremendous worldwide market potential.

Business:

Nerve Access is developing a pharmaceutical product (named NA135) to treat Alzheimer’s disease (AD).  The active ingredient of NA135 is an approved pharmaceutical that has been used to treat a common disease for decades and has proven to be very safe.  The route of administration chosen is very novel, delivers the drug directly to the Central Nervous System (CNS) without having to cross the blood brain barrier (BBB), and very convenient for the patient and caregiver.  The rest of the body’s organs will not be exposed to the drug, thus significantly reducing side effects and drug dosage.  Animal research and small clinical trials showed remarkable improvement of the mental capacity both in normal subjects and mentally deteriorated AD patients after the use of the active ingredient.  Furthermore, Nerve Access has developed a stable formula for NA135, whose stability and potency have been tested several times and determined to be up to the US Pharmacopoeia standards.Noteworthy, some inactive ingredients included in the NA135 formula have been reported to have beneficial effects to the mental decline of AD.

Competition:

Currently there are no drugs or therapies that have been proven to have a long-term ability to meaningfully treat AD.  Our product is unique because it provides dramatic and significant improvement of the mental decline experienced in AD patients.  Second, it is proven to be a disease-modifying therapeutic, i.e. they act to reverse the pathology of AD.  Third, the new route of administration carries the following advantages: 1] very convenient for the patient and caregiver; and 2] delivers the drug directly to the brain without having to cross BBB thus does not expose the rest of the body organs to the drug and its side effects.   Examples of AD drugs approved by the FDA are donepezil, galantamine, rivastigmine, memantine, and tacrine; the latter is almost obsolete due to its hepatotoxicity.  None of these drugs use the same convenient route of administration.

 Click Here for Our Privacy Policy

Check the website of our associate corporation The Neural Repair Institute

Check the website of our associate corporation Broad Enterprises, Inc.

Attachments:
FileDescriptionFile sizeDownloads
Download this file (Review_Essay_for_Alzheimer_s_Disease.pdf)Alzheimer's diseaseAlzheimer's disease PDF80 kB0

Add comment


Security code
Refresh

Recent News

  • Patent Acquisition

    Nerve Access, Inc. is about to acquire some patents from the US Patent Office in support of its novel formulation about the nasal spray to treat Alzheimer's disease.

     
  • Fedral Grant

    Nerve Access, Inc. has received a federal grant of $245,000 to support its research and development of nasal spray to treat Alzheimer's disease.

 
 

Powered by TiknoSoft.com